Alani Omar, Webb Carrington, Memon Nashwah, Rahman S Minhaj, Ahmed Fahad, Seminara Nicole, Haque Adel
Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Piedmont Plastic Surgery & Dermatology, Charlotte, NC, USA.
J Psoriasis Psoriatic Arthritis. 2025 Jun 2:24755303251345804. doi: 10.1177/24755303251345804.
Biologic dosing frequency is a key concern among psoriasis (PsO) patients and physicians, yet dosing optimization remains a challenge. This study evaluates patient dosing preferences for IL-17 and IL-23 inhibitors, risankizumab (RZB) every 12 weeks, guselkumab (GUS) every 8 weeks, and ixekizumab (IXE) every 4 weeks, in managing PsO. This phone survey study evaluated 87 adults on RZB (n = 29), GUS (n = 35), or IXE (n = 23) from 2019 onward at two clinical sites. Patients were assessed for baseline PsO bothersome severity, current dosing frequency satisfaction, frequency of PsO flares, and preferred dosing frequency. Most patients were males (57.5%) with an average age of 54.1 years and an average treatment duration of 19.0 months. At baseline before treatment, 87% were 'very bothered' by their PsO. After treatment, 86% were either '3-somewhat' or '4-very satisfied' with their current dosing schedule, with no significant differences between each drug ( = 0.7). Across all biologics the majority of participants (62% with RZB, 57% with GUS, and 48% with IXE) preferred maintaining their current dosing frequency. No statistically significant differences were observed in dosing frequency preference between treatment groups, suggesting dosing schedule is not a primary concern for most patients. This aligns with previous research demonstrating effective disease control is the most important factor for patient satisfaction; however, tailoring dosing regimens to individual patient needs can also strengthen long-term adherence, as demonstrated in recent studies.
生物制剂给药频率是银屑病（PsO）患者和医生共同关注的关键问题，但给药方案的优化仍然是一项挑战。本研究评估了银屑病患者对白细胞介素-17和白细胞介素-23抑制剂的给药偏好，包括每12周一次的司库奇尤单抗（RZB）、每8周一次的古塞库单抗（GUS）和每4周一次的依奇珠单抗（IXE）在银屑病治疗中的应用。这项电话调查研究评估了自2019年起在两个临床地点接受RZB（n = 29）、GUS（n = 35）或IXE（n = 23）治疗的87名成年人。对患者的银屑病基线困扰严重程度、当前给药频率满意度、银屑病发作频率以及偏好的给药频率进行了评估。大多数患者为男性（57.5%），平均年龄54.1岁，平均治疗时长19.0个月。治疗前基线时，87%的患者因银屑病“非常困扰”。治疗后，86%的患者对当前给药方案“有点满意”或“非常满意”，各药物组之间无显著差异（ = 0.7）。在所有生物制剂中，大多数参与者（使用RZB的为62%，使用GUS的为57%，使用IXE的为48%）倾向于维持当前给药频率。各治疗组间在给药频率偏好上未观察到统计学显著差异，这表明给药方案并非大多数患者的主要关注点。这与先前的研究一致，即有效控制疾病是患者满意度的最重要因素；然而，根据个体患者需求调整给药方案也可增强长期依从性，近期研究已证实这一点。
